Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.
Kubicki T, Jamroziak K, Robak P, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Wróbel T, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Kruk-Kwapisz D, Derman BA, Major A, Jakubowiak AJ, Dytfeld D. Kubicki T, et al. Among authors: druzd sitek a. Pol Arch Intern Med. 2024 May 28;134(5):16749. doi: 10.20452/pamw.16749. Epub 2024 May 14. Pol Arch Intern Med. 2024. PMID: 38747414 Free article. Clinical Trial. No abstract available.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Griffith K, Stefka A, Major A, Derman BA, Jakubowiak AJ. Dytfeld D, et al. Among authors: druzd sitek a. Lancet Oncol. 2023 Feb;24(2):139-150. doi: 10.1016/S1470-2045(22)00738-0. Epub 2023 Jan 12. Lancet Oncol. 2023. PMID: 36642080 Free PMC article. Clinical Trial.
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Kubicki T, Dytfeld D, Wróbel T, Jamroziak K, Robak P, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Zaucha JM, Mikulski D, Czabak O, Lahoud OB, Stefka A, Derman BA, Jakubowiak AJ. Kubicki T, et al. Among authors: druzd sitek a. Br J Haematol. 2023 Dec;203(5):792-802. doi: 10.1111/bjh.19097. Epub 2023 Sep 10. Br J Haematol. 2023. PMID: 37691005 Clinical Trial.
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.
Kubicki T, Dytfeld D, Barnidge D, Sakrikar D, Przybyłowicz-Chalecka A, Jamroziak K, Robak P, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Wróbel T, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Jiang K, Cooperrider JH, Jakubowiak AJ, Derman BA. Kubicki T, et al. Among authors: druzd sitek a. Blood. 2024 Aug 29;144(9):955-963. doi: 10.1182/blood.2024024041. Blood. 2024. PMID: 38713888 Free PMC article. Clinical Trial.
A Stepwise Screening Protocol for Multiple Myeloma.
Morawska M, Dwilewicz-Trojaczek J, Stompór T, Ligocki P, Stopiński M, Sutkowski M, Grząśko N, Kordecka A, Kordecki M, Jurczyszyn A, Dytfeld D, Wróbel T, Jamroziak K, Druzd-Sitek A, Walter-Croneck A, Giannopoulos K. Morawska M, et al. Among authors: druzd sitek a. J Clin Med. 2023 Feb 8;12(4):1345. doi: 10.3390/jcm12041345. J Clin Med. 2023. PMID: 36835883 Free PMC article.
Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium.
Iskierka-Jażdżewska E, Canzian F, Stępień A, Martino A, Campa D, Stein A, Krawczyk-Kuliś M, Rybicka-Ramos M, Kyrcz-Krzemień S, Butrym A, Mazur G, Jurczyszyn A, Zawirska D, Grząśko N, Tomczak W, Subocz E, Wątek M, Pasiarski M, Rymko M, Całbecka M, Druzd-Sitek A, Walewski J, Kruszewski M, Raźny M, Zaucha JM, Dudziński M, Gaj P, Robak T, Warzocha K, Jamroziak K. Iskierka-Jażdżewska E, et al. Leuk Lymphoma. 2020 Mar;61(3):699-706. doi: 10.1080/10428194.2019.1689391. Epub 2019 Nov 20. Leuk Lymphoma. 2020. PMID: 31746254
Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
Grzasko N, Hajek R, Hus M, Chocholska S, Morawska M, Giannopoulos K, Czarnocki K, Druzd-Sitek A, Pienkowska-Grela B, Rygier J, Usnarska-Zubkiewicz L, Dytfeld D, Kubicki T, Jurczyszyn A, Korpysz M, Dmoszynska A. Grzasko N, et al. Leuk Lymphoma. 2017 Sep;58(9):1-15. doi: 10.1080/10428194.2016.1272684. Epub 2017 Jan 16. Leuk Lymphoma. 2017. PMID: 28092996
Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.
Usnarska-Zubkiewicz L, Dębski J, Butrym A, Legieć W, Hus M, Dmoszyńska A, Stella-Hołowiecka B, Zaucha JM, Januszczyk J, Rymko M, Torosian T, Charliński G, Lech-Marańda E, Malenda A, Jurczyszyn A, Urbańska-Ryś H, Druzd-Sitek A, Błońska D, Urbanowicz A, Hołojda J, Pogrzeba J, Rzepecki P, Hałka J, Subocz E, Becht R, Zdziarska B, Dytfeld D, Nowicki A, Bołkun Ł, Kłoczko J, Knopińska-Posłuszny W, Zubkiewicz-Kucharska A, Kuliczkowski K. Usnarska-Zubkiewicz L, et al. Leuk Res. 2016 Jan;40:90-9. doi: 10.1016/j.leukres.2015.11.005. Epub 2015 Nov 15. Leuk Res. 2016. PMID: 26626207
Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group.
Grzasko N, Charlinski G, Morawska M, Kicinski P, Waszczuk-Gajda A, Drozd-Sokolowska J, Subocz E, Blonska D, Razny M, Druzd-Sitek A, Holojda J, Swiderska A, Usnarska-Zubkiewicz L, Masternak A, Giannopoulos K. Grzasko N, et al. J Clin Med. 2021 Nov 24;10(23):5504. doi: 10.3390/jcm10235504. J Clin Med. 2021. PMID: 34884206 Free PMC article.
33 results